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Solid-phase synthesis of branched oligonucleotides containing the biologically 
relevant dCyd341 interstrand crosslink DNA lesion†.
Marisa L. Taverna Porroa,b, Christine Saint-Pierrea, Didier Gasparuttoa and Jean-Luc Ravanata*
Branched oligonucleotides containing a biological relevant DNA lesion, dCyd341 that involves an interstrand crosslink 
between a cytosine base on one strand and a ribose moiety of the opposite strand, was prepared in a single automated 
solid-phase synthesis. For this, we first prepared the phosphoramidite analogue of dCyd341 bearing an orthogonal levulinyl 
protecting group. Then, following synthesis of the first DNA strand containing dCyd341, levulinic group was removed and 
synthesis was then continued from the free base hydroxyl group at the branching point, using traditional phosphoramidites. 
The synthesized oligonucleotides were fully characterized by MALDI-TOF/MS, were enzymatically digested and the presence 
of the lesion was confirmed by LC/MS-MS and sequence was finally controlled upon exonucleases digestion followed by 
MALDI-TOF/MS analysis. The developed strategy was successfully employed for the preparation of several short linear and 
branched oligonucleotides containing the aforementioned lesion.
Introduction
Oxidative stress is known to be implicated in several biological 
disorders and associated with diverse pathologies.1-3 In 
particular, reactive oxygen species are known to induce 
chemical modifications to biomolecules. DNA is one of the main 
cellular targets of oxidative stress and the produced DNA lesions 
can contribute to the initiation and/or propagation processes 
that can lead to carcinogenesis through mutagenesis.4 To 
reduce the deleterious effects of these modifications, cells have 
developed efficient DNA repair systems able to excise these 
lesions and restore DNA integrity.
Complex or clustered DNA lesions, including tandem lesions, 
double strand breaks and interstrand crosslinks (ICLs)5 involve 
several chemical modifications of the DNA structure in one helix 
turn.2,6 For ICLs the covalent tethering of both duplex strands 
prevents their separation; blocking essential biological 
processes such as DNA replication and transcription.7 Thus, ICLs 
represent a challenge for the DNA repair machinery. Their 
repair involves nucleotide excision repair (NER), homologous 
recombination (HR) and non-homologous end joining (NHEJ) 
pathways, but a lot is still unclear.7 If left unrepaired, they can 
provoke chromosomal breakages, rearrangements, genomic 
instability and aging in tissue and organs.8 Such a toxic effect is 
the principle of action of many antitumoral drugs currently used 
in cancer therapy.9 
The ICLs lesions can be exogenously formed by action of 
chemical agents such as bifunctional alkylating agents including 
platinum compounds and psolaren.10 Recent results11 have 
indicated that they could also be generated as a consequence 
of a single ionization process, and therefore by endogenous 
oxidative stress, ionizing radiation and radiomimetic drugs. This 
concerns lesions generated through the transient formation of 
reactive intermediates (aldehydes or radicals) on one DNA 
strand, that may further react with surrounding DNA bases.12 
Regarding this last type of damage, a lesion named dCyd341, 
identified by our laboratory, was found to be generated in 
significant amounts in cellular DNA even by endogenous 
oxidative stress,13 whereas its repair rate (half-life of about 10h 
in culture cells) was rather slow compared to classical oxidative 
DNA lesions. It was clearly demonstrated that dCyd341 is a 
complex DNA lesion generated by a single ionization process 
(scheme 1).13 Indeed, the initial event leading to formation of 
the lesion involves hydrogen abstraction at the C4´ position of 
the 2-deoxyribose moiety of DNA with the concomitant 
formation of the corresponding C4’ radical. Decomposition of 
that radical (1, Scheme 1) gives rise to the formation of a 
modified sugar residue bearing a reactive aldehyde (2, Scheme 
1). This transiently generated aldehyde is able to add onto a 
cytosine base (and also adenine14) located onto the opposite 
strand thus generating through successive steps to the four 
possible diastereomers of dCyd341 (Fig S1). Such a mechanism 
generates a strand break and an interstrand crosslink (Schemes 
1 and 2).
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Scheme 2. Formation of dCyd341 (3) initiated by nucleophilic addition 
of the amino group of cytosine onto the reactive aldehyde 2.
Therefore, it is of particular interest to determine i) the 
biological relevance of this lesion, ii) its kinetics and efficacy of 
elimination by DNA repair processes and iii) its mutagenic 
potential. It is well known that the extensive study of ICLs is 
hampered by the difficulty in the preparation of suitable 
substrates that are required to perform biochemical studies. 
One of the biggest challenges in the characterization of ICLs at 
the molecular level is the preparation of short oligonucleotide 
(ON) duplexes containing a single cross-link at a specified and 
well-defined location in the DNA sequence. 
Nevertheless, several strategies for their preparation have 
already been investigated. For example, direct treatment of 
DNA with bifunctional agents has been reported.15,16 This 
strategy often gives rise to a complex spectrum of products and 
the desired modification could only be isolated in small yields. 
Another methodology involves the construction of short DNA 
sequences bearing a reactive residue (or an activatable one) 
towards the complementary strand. Even if such a strategy was 
employed successfully in the synthesis of several short ICLs 
duplexes, it presents a general disadvantage of lack of 
specificity and instability (to see some examples17-21). Another 
strategy consists in using an orthogonal protecting group. This 
approach involves the synthesis of DNA oligomers on a solid-
phase automated DNA synthetizer, incorporating a modified 
nucleoside phosphoramidite with an orthogonal protecting 
group as the branching point. Once the first DNA strand is 
synthesized, the orthogonal protecting group can be selectively 
removed leaving the protected DNA strand attached on the 
solid support. The branched sequence can then be completed 
from the unprotected branching point, using the solid-phase 
automated DNA synthetizer. This methodology has been 
successfully applied for site specific synthesis of RNA22 and 
DNA.23 
In this work, we report the first synthesis of branched 
oligonucleotides containing the biological relevant dCyd341 
lesion. For this, we have successfully prepared the dCyd341 
phosphoramidite analogue bearing an orthogonal protecting 
group at the branching point. It was then used for the 
preparation of short linear and branched oligonucleotides 
containing the aforementioned DNA lesion.
Results and discussion
Synthesis of dCyd341 phosphoramidite
The targeted phosphoramidite synthon (11, Scheme 3) for this 
strategy is shown in Scheme 3. The levulinyl group was chosen as the 
orthogonal protecting group since, as previously reported,24  it can 
be easily removed using hydrazine without affecting the other 
protective functions of the DNA oligomer. The base modification can 
be achieved, as already described by our group13, by reaction of the 
protected nucleoside with the levulinated conjugated aldehyde. 
Therefore, the first step of this synthetic strategy was the 























Scheme 3. Synthetic strategy of phosphoramidite synthon 11.
For this, furfuryl alcohol was acylated using levulinic acid and DCC to 
give furfuryllevulinate (4, Scheme 4) in quantitative yields. Oxidation 
of 4 was then investigated. Then, the protected furfuryl derivative 
was oxidized using different oxidizing reagents, namely ozone, 3-
chloroperoxybenzoic acid (MCPBA) and N-bromosuccinimide (NBS). 
When MCPBA was used only 8% of the furan moiety was converted 
into the aldehyde after 2 days of reaction. Ozone-mediated oxidation 
of 4 led to total conversion of the starting material, but only small 
amounts of the desired aldehyde were recovered. NBS oxidation 
gave the best results, generating the trans 2,5-dioxo-pent-3-enyl 












Scheme 4. Chemical synthesis of 2,5-dioxo-pent-3-enyl levulinate 5.  
The reaction mixture of 5 was then incubated in the presence of the 
protected deoxycytidine to give the adduct 6 in high yields (90 %, 
Scheme 5). The reaction is supposed to occur by initial attack of the 
exocyclic amine followed by 1,4-addition of the adjacent endocyclic 
nitrogen atom to the double bond, to generate an 
oxadiazabicyclo(3.3.0)octaimine adduct 6. Even though mass 
spectrometry analysis of the purified adduct exhibit the expected 
molecular weight (m/z = 856 Da, positive mode) this compound could 
not be unambiguously characterized by NMR, even using 2D COSY, 
HSQC and HMBC NMR spectra (Fig S2, S3, S4, S5, S6) due to the 
presence of several diastereomers5 (chemical structures of all 
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possible diastereomers are presented in Fig. S1). However, high 
resolution mass spectrometry of compound 6 (Fig. S7) is in 
agreement with the proposed structure. For further confirmation, 
the oxidized furfuryl levulinate derivative 5 was incubated in the 
presence of 2-deoxycytidine. The obtained products were then 
treated under alkaline conditions to remove the levulinyl group and 
analyzed by HPLC-MS/MS. The synthesized products, which appear 
as four modified nucleosides, were found to exhibit the same HPLC 
retention times and mass spectroscopic features as the four isomers 
of dCyd341, whose structures has been previously characterized in 













































































7,8 (63% yield 3: 1 by 1H NMR)
9,10 (69% yield)
11 (60% yield)




Scheme 5. Synthesis of dCyd341 phosphoramidite 11.  
The modified nucleoside 6 was then acetylated using acetic 
anhydride in pyridine and the reaction mixture was then purified by 
silica gel chromatography. Two major fractions were collected and 
analyzed by mass spectrometry. ESI+ MS analysis of the first fraction 
revealed a major compound with m/z=880 Da (12, Scheme 5), 
whereas the second fraction contained a mixture of two products 
with molecular weights of 837 (8, Scheme 5) and 897 (7, Scheme 5), 
the last being the molecular weight of the desired acetylated 
compound. Further insight into the structures of these compounds 
was obtained from tandem mass spectometry and 1H-NMR. The 
MS/MS fragmentation patterns (Fig S9) presented the predominant 
loss of the protected sugar, confirming that the difference in mass 
could be attributed to the base moieties (m/z = 348, 306 and 368 for 
12, 8 and 7, respectively). MS2 fragmentation of 12 exhibited a major 
secondary product ion at m/z = 306 and the same MS3 fragmentation 
pattern to the 8 BH2+ fragment, suggesting that the differences 
between these two compounds was an acetyl group. The ∆m/z 
between 12 and 7 was 18 Da, indicating that 12 could be formed by 
a dehydration reaction of compound 7 (Scheme 5). Efforts were then 
made to separate small amounts of each compound presented in the 
second fraction. Although these compounds could not be fully 
separated, small amounts of compound 8 was recovered and 
characterized by 1H-NMR. The aromatic region of the 1H-NMR 
spectra recorded for compounds 12 and 8 was characterized by two 
singlets at around 7.63 ppm (B, Fig. 1) and one singlet at 7.22 ppm 
(A, Fig. 1) respectively, and these signals were missing for compound 
7. The 1H NMR spectrum of 12 and 7 also showed the presence of the 
CH3 signals of the acetyl group at around 2 ppm (not shown), 
whereas this signal was absent for compound 8. 
Taking all of the analysis into account, our results suggest that 7 is 
the desired acetylated adduct, 8 being its dehydrated product 
formed by the elimination of the acyloxy group elicited by the 
acetylation reaction. Its formation may be rationalized as an 
enolization followed by an acetyl migration and subsequent 
dehydration. The driven force for this last reaction could be the 
greater stability derived from the extended conjugation of the 
generated product. Other acetylation conditions as well as other 
acylating reagents were studied in order to avoid the formation of 
these by-products. Whatever the conditions used, the dehydration 
product 8 was always generated.
Fig. 1. Partial 1H-NMR sepectra (5-8 ppm) of acetylation products 7 (red), 8 
(blue) and 12 (green). Interesting protons are highlighed (see discussion).
The synthesis of the phoshoramidite was continued with the mixture 
of acetylated compounds 7 and dehydration product 8. For this, the 
tert-butyldimethylsilyl (TBDMS) group was selectively removed by 
treating the mixture of 7 and 8 with tetrabutylammonium fluoride 
(TBAF) in THF, yielding a mixture of free 3´-hydroxy derivatives 9 and 
10. Finally, the resulting mixture was phosphitylated using excess of 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite. Fortunately, 
for compound 10, the oxygen atom connected as an enol to the 
aromatic base was also reactive towards the phosphitylating 
reagent, affording two chromatographically separable 
phosphoramidite derivatives, desired compound 11 (60 %, Scheme 
5) and biphosphitylated compound 13 (Chemical structure presented 
in Fig. S10). 
Oligonucleotide synthesis
The strategy for the solid-phase synthesis of the branched 
oligonucleotide is shown in Scheme 6. The first step involves the 
traditional solid-phase synthesis of oligonucleotides with the 
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incorporation of the modified phosphoramidite bearing the 
branching point. Once the linear strand is completed, an acetylation 
step is performed in order to block further elongation at the 5’-end 
of the oligomer. The protecting group of the branching point is then 
selectively removed and the synthesis of the branched 
oligonucleotide is continued.
Scheme 6. Strategy for the synthesis of branched oligonucleotides bearing 
dCyd341.
First, in order to determine the ability to incorporate the modified 
phosphoramidite into oligonucleotides, regular non-branched 
oligomers of several lengths were prepared as listed in Table 1 (14, 
15, 17 and 18). The modified oligonucleotides were synthesized using 
standard fast deprotection phosphoramidite chemistry with cycles 
including detritylation, coupling, capping and oxidation. The 
syntheses were initiated by constructing the linear strand using 
standard amidite concentration and coupling times. However, when 
the branching monomer phosphoramidite 11 was incorporated, a 
coupling time of 15 min was applied. Under these conditions, the 
coupling efficiency was almost quantitative. The oligonucleotides 
were then cleaved from the solid support and deprotected by 
treatment with concentrated ammonia for 5 h at room temperature 
(approximately yields 60 % for all oligonucleotides synthesized). The 
released oligonucleotides were purified by HPLC to give the 
deprotected oligonucleotides. These oligonucleotides were analyzed 
by MALDI-TOF/MS and the observed molecular weights supported 
the incorporation of the modified phosphoramidite onto the 
oligonucleotides (Fig S11 and Table 1).
In order to fully characterize the modified oligonucleotides, the 
purified oligomers were enzymatically digested and analyzed by 
HPLC/MS-MS. In all of the digested samples, for both linear and 
branched oligomers, a compound with a molecular mass 
corresponding to dCyd341 and at the expected retention time was 
observed (Fig. S12). No appreciable amount of the dehydration 
product was detected. For preparing the branched oligonucleotides, 
a separate end-capping cycle (consisting of detritylation and 
acetylation) was used to block further elongation at the 5’-end. 
Thereafter, the support was treated with a 0.5 M solution of 
hydrazine hydrate in pyridine:acetic acid for 15 min to remove the 
levulinyl protecting group. Synthesis was then continued in the 
normal fashion from the free base hydroxyl group at the branching 
point, using traditional phosphoramidites. The molecular weight of 
the ONs was determined by MALDI-TOF/MS (Fig. S11 and Table 1). 
As expected, both the non-branched 15 and branched 
oligonucleotides 16 of the same length share the same molecular 
weight.
Table 1. Oligonucleotides sequences and masses determined by MALDI-
TOF/MS and compared to theoretical calculations.
Then, to verify the successful synthesis of the branched oligomers 
two different analyses were performed. For practical purposes, the 
analyses were carried out with the shortest sequences (15 and 16, 
Table 1). First, examination of the HPLC profiles of the purified 
branched and non-branched oligonucleotides reveals different 
chromatographic behaviors, both oligonucleotides having different 
retention times (A and B, Fig. 2). The co-injection of a mixture of 
them confirmed this assumption as shown in panel C (Fig. 2). 
Fig. 2. HPLC chromatographic profiles of: A. 15, B. 16 and C. Co-injection of 15 
and 16.
Finally, controlled phosphodiesterease digestions followed by 
MALDI-TOF/MS analysis was performed. Oligonucleotides were 
partially digested with 3'  5' and 5'  3' acting exonucleases in a 
MALDI-TOF/MS compatible buffer. The partial digests were analyzed 
by MALDI-TOF mass spectrometry and the sequence was inferred 
from the mass differences between adjacent peaks (Table 2).
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Surprisingly, digestion of branched oligonucleotides was faster than 
that of the corresponding non-branched ones. The MALDI-TOF/MS 
profiles for the 3'  5' digestion are, as expected, similar for both 
oligonucleotides (Table 2B and 2D, Fig. S13), showing both the 
sequential loss of dC and dA. For 5'  3' digestion, the profiles are 
quite different (Table 2A and 2C, Fig. S14). For the non-branched 
oligonucleotide (Table 2A), the enzymatic hydrolysis proceeds up to 
one nucleotide before the modification, observing peaks at m/z = 
1880, 1576 and 1245 corresponding to the sequential loss of dC, dT 
and dG, respectively. For the branched oligonucleotide (Table 2C) 
only two nucleotides were lost before the digestion dramatically 
stopped (m/z 1880, 1840 and 1550, Table 2). The peak at m/z = 1880 
corresponds to the loss of one dG, only possible for the branched 
sequence whereas the peak at m/z = 1840 correspond to the loss of 
dC. The fragment observed at 1551, corresponding to the loss of both 
dG and dC is also only possible in a branched sequence. 
Altogether, the obtained results clearly demonstrate that after 
deprotection of the orthogonal levulinyl group and further 
elongation, we can prepare the biologically relevant branched 
oligonucleotides containing the dCyd341 lesion. 
Table 2. Application of exonuclease digestion together with MALDI-TOF/MS 
analysis for the characterization of branched (16) and non-branched 
oligonucleotides (15). MW observed for the: A. 5’-3’ digestion of 15, B.3’-5’ 
digestion of 15, C.5’-3’ digestion of 16  and D. 3’-5’ digestion of 16.
Conclusions
We have developed a single automated chemical synthesis of a 
branched oligonucleotide bearing a biologically relevant lesion. For 
this, we have successfully prepared a phosphoramidite derivative 
bearing an orthogonally protected group at the branching point. We 
have shown that this phosphoramidite building block could be 
incorporated into oligonucleotides of different lengths and could be 
used, after deprotection, to produce branched oligonucleotides. 
Preparation of longer oligonucleotides will be performed in order to 
use them for biological studies including the study of repair and 
mutagenicity of the dCyd341 interstrand crosslink.
Experimental 
Instrumentation. Oligonucleotides were prepared on a 392 DNA 
synthesizer (Applied Biosystems Inc, Palo Alto, CA). The HPLC-MS/MS 
analyses were performed with a triple quadrupole mass 
spectrometer TSQ Quantum Ultra from Thermo Scientific equipped 
with a Thermo Accela Pump, a Accela autosampler and a Accela 
photodiode array detector. The data were processed using Xcalibur 
software. HPLC purification was performed using a Agilent 1200 
Series LC system. 1H NMR spectra were recorded on a Brucker 
Avance DMX 200 at 295 K in 400 µL of either CCl3D. The MALDI-
TOF/MS mass spectra were obtained in the negative mode on a time-
of-flight Microflex mass spectrometer (Bruker), equipped with a 337-
nm nitrogen laser and pulsed delay source extraction. The matrix was 
prepared by dissolving 3-hydroxypicolinic acid in 10 mM ammonium 
citrate buffer. Prior to MALDI-TOF mass analysis, oligonucleotide 
solutions were purified and concentrated on ZipTip pipette tips 
(Millipore). A mixture of purified DNA sample (10 pmol; 1 µl) was 
added to matrix (1 µl) and spotted on a polished stainless target plate 
using the dried droplet method. Spectra were calibrated using 
reference oligonucleotides of known masses.
Synthesis of dCyd341 phosphoramidite
Furfuryllevulinate (4). To a solution of furfuryl acohol (0.5 ml, 5.8 
mmol), DCC (3.0 g, 14.6 mmol) and DMAP (70 mg, 0.6 mmol) in THF 
(100 ml),  20 ml of a THF solution of levulinic acid (1.2 ml, 11.6 mmol) 
was added. After 3 h with stirring at room temperature the mixture 
was carefully filtered and the supernatant was evaporated. The 
resulting residue was dissolved in DCM, and washed successively 
with saturated sodium bicarbonate, water and brine. Finally it was 
dried over Na2SO4 and concentrated at reduced pressure to give 
compound 4 in quantitative yields. 1H NMR (Fig S15) (200 MHz, 
Cl3CD) (ppm) 7.39 (dd, J = 1.8, 0.9 Hz, 1H), 6.38 (d, J = 3.2Hz, 1H), 
6.33 (dd, J = 3.2, 1.8 Hz, 1H), 5.03 (s, 2H),  2.73-2.69 (m, 2H),2.60-2.57 
(m, 2H) 2.15 (s, 3H). MS m/z 235 (M + K+), 219 (M + Na+), 197 (M+H+).
Trans 2,5-dioxo-pent-3-enyl levulinate (5). Compound 4 (1.13 g, 5.8 
mmol) was dissolved in a mixture of acetone:water 10:1 (25 ml) and 
placed in a cooling bath at – 20 °C.  NaHCO3 (1.00 g, 11.9 mmol) was 
added to the cooled solution. A solution of N-bromosuccinimide 
(NBS) (1.22 g, 6.85 mmol) in the same solvent (16 ml) was then added 
dropwise with stirring. After the addition was complete the reaction 
was stirred for 1 h at -20 °C. The reaction was then quenched by 
addition of pyridine (2 ml, 20 mmol) and removed from the cooling 
bath. It was then allowed to warm at room temperature and stirred 
for 2 additional hours. The mixture was poured onto EtAcO and 
extracted several times with HCl 5%, H2O, saturated sodium 
bicarbonate and brine. Finally, it was dried over Na2SO4 and 
concentrated at reduced pressure to give a crude mixture with 75 % 
yield of compound 5 (measured by 1H-NMR). The crude mixture was 
subsequently used without further purification. 1H NMR (Fig. 
S16)(200 MHz, Cl3CD) δ (ppm) 9.77 (d, J = 7.0 Hz, 1H), 7.40 (m, 0.4H), 
7.04 (d, J = 16.2 Hz, 1H), 6.83 (dd, J = 16.2, 7.0 Hz, 1H), 6.38-6.34 (m, 
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0.8H), 5.03 (s, 0.8H), 4.90 (s, 2H),  2.87 – 2.48 (m, 5.6 H), 2.17 (s, 3H), 
2.15 (s, 1.2 H).
6-(5´-O-(DMTr)-3´-O-TBDMS-2´-D-deoxyribofuranosyl)-2-hydroxy-
3(3-hydroxy-2-oxopropyl)-2,6-dihydro-imidazo[1,2-c]-pyrimidin-
5(3H)-one (5´-O-DMT-3´-O-TBDMS-dCyd341) (6). To a stirring 
solution of the protected deoxycytidine prepared as previously 
described25 (0.6 g, 0.9 mmol) in DCM (15 ml) a solution of 5 (1.20 g 
.4.5 mmol) in the same solvent (10 ml) was added dropwise under Ar 
atmosphere and the reaction mixture was then stirred overnight at 
room temperature. Afterwards, the reaction mixture was washed 
successively with saturated sodium bicarbonate, water and brine. 
Finally it was dried over Na2SO4 and concentrated at reduced 
pressure. The resulting oil was purified by flash column 
chromatography (DCM:MeOH 100:3) to give compound 6 as brown 
oil (93 % yield).1H NMR (Fig S17) (200 MHz, Cl3CD) δ (ppm)  7.32 – 
7.29 (m, 10H), 6.84 – 6.79 (m, 4H), 6.35 – 6.16 (m, 2H), 5.53 – 5.50 
(m, 1H), 4.77 – 4.68 (m, 1H), 4.57 – 4.48 (m, 1H),  4.27-4.18 (m, 2H), 
3.97 – 3.92 (m, 1H), 3.82 (s, 6H),  3.43 – 3.31 (m, 2H), 2.90 – 2.78 (m, 
5H), 2.22 (s, 3H), 0.87  (s, 9H), 0.07 – 0.01 (m, 6H).ESI MS m/z 856 
(M+H+), 324 (BH2+), 303 (DMTO+).
6-(5´-O-(DMTr)-3´-O-TBDMS-2´-D-deoxyribofuranosyl)-2-O-Acetyl-
3(3-hydroxy-2-oxopropyl)-2,6-dihydro-imidazo[1,2-c]-pyrimidin-
5(3H)-one (5´-O-DMT-3´-O-TBDMS-2-O-Ac-dCyd341) (7). To a 
solution of compound 6 (0.74 g, 0.9 mmol ) in pyridine (6 ml) acetic 
anhydride (0.16 ml, 1.8 mmol) and catalytic amounts of DMAP were 
added under Ar atmosphere. The mixture was stirred overnight at 
room temperature and then concentrated under reduced pressure 
to dryness. The residue was dissolved in DCM and then was washed 
successively with saturated sodium bicarbonate, water and brine. 
Finally, it was dried over Na2SO4 and concentrated at reduced 
pressure. The resulting oil was purified by flash column 
chromatography (DCM:MeOH 100:1) to give compound 12 (30 % 
yield) and the mixture of 7 : 8 (63% yield, 3:1 by 1H-NMR). Mixture of 
compounds 7 and 8. 1H NMR (Fig S18) (200 MHz, Cl3CD)  δ (ppm) 
7.72-7.59 (m, 1H (7 and 8)), 7.42– 7.29 (m, 10H), 7.19 (s, 0.2H (8)), 
6.89 – 6.85 (m, 4H), 6.52 – 6.45 (m, 0.8H(7)), 6.45 – 6.33 (m, 1H (7 
and 8)), 6.26 (m, 0.2H (8)), 5.58 (m, 0.8H (7)), 4.90 (s, 0.4H (8)), 4.70 
– 3.91(several peaks, m, 5.4H(7 and 8)), 3.83 (s, 6H), 3.56 – 3.36 (m, 
2H(7 and 8)), 2.84 – 2.58 (m, 6H(7 and 8)), 2.21 – 2.07 (several 
singlets, 5.4H (7 and 8)),  0.85  (s, 9H (7 and 8)), 0.12 – 0.01 (m, 6H (7 
and 8)). ESI MS m/z 898 (M+H+), 838 (M+H+), 366 (BH2+), 306 (BH2+), 
303 (DMTO+). Compound 8 (enriched for characterization, Fig. S19) 
1H NMR (200 MHz, Cl3CD)  δ (ppm) 7.70 (d, J = 7.9 Hz, 1H), 7.40 – 7.30 
(m, 10H) 7.21 (s, 1H), 6.92 – 6.86 (m, 4H), 6.45 (t, J = 5.8 Hz, 1H), 6.25 
(d, J = 7.9 Hz, 1H), 4.91  (s, 2H), 4.60 (q, J = 5.1 Hz, 1H), 4.19 (s, 2H), 
4.00 – 3.96 (m, 1H), 3.83  (s, 6H), 3.56 (dd, J = 10.8, 2.8 Hz, 1H), 3.37 
(dd, J = 10.8, 2.9 Hz, 1H), 2.95-2.71 (m, 5H), 2.48-2.43 (m, 1H), 2.24  
(s, 3H), 0.86  (s, 9H), 0.06  (s, 3H), 0.00  (s, 3H). ESI MS m/z 838 (M+H+), 
306 (BH2+), 303 (DMTO+). Compound 12. 1H NMR (Fig S20) (200 MHz, 
Cl3CD) δ (ppm) 7.81 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.62 (s, 1H), 7.46 
-7.31 (m, 10H), 6.89 – 6.85 (m, 4H), 6.49 (t, J = 5.7 Hz, 1H), 6.31 (d, J 
= 7.9 Hz, 1H), 4.89  (s, 2H), 4.59 (q, J = 5.2 Hz, 1H), 4.12 – 4.02 (m, 1H), 
3.82  (s, 6H), 3.59 (dd, J = 10.8, 2.6 Hz, 1H), 3.55 (dd, J = 10.8, 2.7 Hz, 
1H), 2.94-2.77 (m, 3H), 2.69-2.63 (m, 2H), 2.54-2.41 (m, 1H), 2.32  (s, 
3H), 2.22  (s, 3H), 0.86  (s, 9H), 0.05  (s, 3H), 0.00  (s, 3H). ESI MS m/z 
880 (M+H+), 348 (BH2+), 303 (DMTO+). 
6-(5´-O-(DMTr)-2´-D-deoxyribofuranosyl)-2-O-Acetyl-3(3-hydroxy-
2-oxopropyl)-2,6-dihydro-imidazo[1,2-c]-pyrimidin-5(3H)-one (5´-
O-DMT-2-O-Ac-dCyd341 ) (9). A mixture of 7 and 8 (0.5 g, 0.6 mmol) 
in THF (30 mL) and Bu4NF (1.2 mmol, 1.2 mL in 1 M THF solution) was 
stirred under Ar atmosphere for 1 h at 0°C. The reaction mixture was 
then diluted with ether (60 mL) and washed with water, brine, and 
dried over Na2SO4. After solvent was evaporated, the residue was 
purified by column chromatography (DCM:MeOH:Et3N 100:1:0.5) to 
give the mixture of compound 9 and 10 in 69 % yield.1H NMR (Fig 
S21) (200 MHz, Cl3CD)  δ (ppm) 7.77-7.43 (m, 1H), 7.36– 7.29 (m, 
10H), 7.16 (s, 0.5H), 6.98 – 6.85 (m, 4H), 6.50 – 6.26 (m, 2H), 5.34 (s, 
1H),4.90 (s, 1H), 4.70 – 4.58(m, 1.5H), 4.43-4.04 (m, 3.5H), 3.82 (s, 
6H), 3.58 – 3.44 (m, 2H), 2.88 – 2.81 (m, 3.5H), 2.77 – 2.33 (m, 4H), 
2.23-1.93 (several singlets, 4H). ESI MS m/z 822 (M + K+), 806 (M + 
Na+), 784 (M+H+), 762 (M’ + K+), 746 (M’ + Na+), 724 (M’+H+), 366 




DMT-2-O-Ac-dCyd341phosphoramidite) (11). 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite (0.23 mL, 1.05 mmol) was added 
to a solution of 9 and 10 ( 0.32g, 0.42 mmol) and DIPEA (0.33 mL,  1.8 
mmol) in DCM (15 mL). The reaction mixture was stirred at room 
temperature for 80 min and then 5% NaHCO3 solution and EtOAc 
were added. The organic layer was separated, dried over Na2SO4, and 
concentrated under reduced pressure. Purification by flash 
chromatography (EtOAc : Et3N 100:0.5) provided 11 (160 mg,  40 %) 
and 13 (145 mg, 31%).  Compound 11.1H NMR (Fig S22) (200 MHz, 
Cl3CD)  δ (ppm)  7.62 (dd, J = 8.0, 10.0  Hz, 1H), 7.43 – 7.30  (m, 10H), 
6.91 – 6.85 (m, 4H), 6.53 – 6.22 (m, 2H), 5.57 – 5.34 (m, 1H), 4.91 – 
4.67 (m, 2H), 4.47 – 4.15 (m, 3H), 3.84 (s, 6H), 3.70 – 3.45 (m, 5H), 
2.88 – 2.32 (m, 10H), 2.21 – 2.08 (several singlets, 3H),  1.63 (s, 3H) 
1.33 – 1.20 (several singlets, 12H). ESI MS m/z 984 (M+H+), 619 (M-
BH+), 366 (BH2+), 303 (DMTO+). Compound 13.1H NMR (Fig S23) (200 
MHz, Cl3CD)  δ (ppm) 7.98 (s, 1H), 7.64 (dd, J = 14.0, 8.0 Hz, 1H), 7.48-
7.30 (m, 10H), 7.13 (s, 1H), 6.91-6.85 (m, 4H), 6.57 (m, 1H), 6.27 (dd, 
J = 7.8, 1.8 Hz, 1H), 5.00 (d, J = 13.1 Hz, 1H), 4.84 (d, J = 13.1 Hz, 1H), 
4.75-4.67 (m, 1H), 4.23-4.18 (m, 1H), 3.99-3.88 (m, 3H), 3.83 (m, 8H). 
3.76-3.47 (m, 7H), 2.88-2.82 (m, 2H), 2.73-2.64 (m, 6H), 2.25 (s, 3H), 
1.26-1.2 (m(several singlets), 24H). ESI MS m/z 1162 (M + K+), 1146 
(M + Na+), 1124 (M+H+), 506 (BH2+), 303 (DMTO+).
Branched oligonucleotide synthesis
Oligonucleotides bearing the modified phosphoramidite were 
prepared using fast deprotection phosphoramidite chemistry. The 
standard 1 µmole DNA cycle with coupling times extended to 15 min 
for the condensation of the modified phosphoramidite. Then, a 
separate end-capping cycle (consisting of detritylation and 
acetylation) was used to block further elongation at the 5’-end. The 
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support was finally manually treated with a 0.5 M solution of 
hydrazine hydrate in pyridine : acetic acid (1:1) for 15 min to remove 
the levulinyl protecting group. Synthesis was then continued in the 
normal fashion from the free base hydroxyl group at the branching 
point, using again traditional phosphoramidite chemistry with 
retention of the 5′ terminal DMT group (DMT-ON). The 
oligonucleotides were removed from the solid support by treatment 
with concentrated ammonia at room temperature for 4 h. Solvents 
were then removed by evaporation under reduced pressure. 
HPLC-UV purification and analysis
The crude oligonucleotide mixtures were purified and deprotected 
on-line by reverse phase HPLC25. Purification was achieved using a 
Hamilton PRP3 polymeric phase column, 10 µm, 305 × 7.0 mm and a 
mixture of acetonitrile and 10 mM TEAA buffer as the eluents [100% 
TEAA (5 min), linear gradient from 0 to 8% of acetonitrile (10 min), 
then isocratic TEAA-acetonitrile (92/8) v/v (10 min). Then, in order to 
remove the DMTr group, column was eluted under isocratic 
condition using 100% TFA (1%) for 10 min and finally a gradient from 
0 to 10% acetonitrile (40 min) with a flow rate of 2.5 mL min-1 was 
used to elute the fully unprotected oligonucleotide. UV detection 
was set at 260 nm. Fractions were collected and the solvent was 
evaporated under reduced pressure. Oligonucleotides were 
characterized by MALDI-TOF/MS and by HPLC-UV. For 
oligonucleotides analyses, chromatographic separations were 
achieved using a mixture of acetonitrile and 10 mM TEAA as the 
eluents [100% 10 mM TEAA (4 min), linear gradient from 0 to 100% 
of acetonitrile (26 min)].
Oligonucleotide digestion and HPLC-MS/MS analysis. 
Incorporation of dCyd341 in oligonucleotides was confirmed by 
HPLC-MS/MS following enzymatic digestion as described in detail 
elsewhere.26 Chromatographic separations were achieved using a 
ODB uptisphere 3 µm 150*2.1 mm column from Interchim under 
linear gradient conditions as previously reported for measuring other 
DNA lesions.27,28 All nucleosides were detected using a UV detector 
set at 260 nm. Multiple reaction monitoring mode was applied for 
the detection of dCyd341 lesion by using transitions 342226, 
342168, and 342148. 
Exonuclease digestion  
Branched and non-branched oligonucleotides (200pmol) were 
dissolved in 15.5 µL of water and 4 µL of 500 mM ammonium citrate 
was added to the solution. For the 3’->5’ digestion, 0.5 µL 
phosphodiesterase I (crotalus venom) (0.03 units/µL) was added to 
the sample solution, whereas for the 5’->3’ digestion, 1 µL of 
phosphodiesterase II (bovine spleen) (0.01 units µ/L) was added. The 
solutions were incubated at 37 °C. Aliquots of the digested solutions 
(1 µL) were removed at fixed periods of time and dissolved in 9 µL of 
water and placed on ice to interrupt the digestion reaction. Aliquots 
(1 – 2 µL) of the samples and the trihydroxyacetophenone matrix 
solution were mixed and immediately spotted on a MALDI-TOF/MS 
target and air-dried before analysis. The mass spectrometer was 
operated in the negative linear mode.
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